Cell and gene therapy manufacturing costs are a significant obstacle to the broader application of these life-saving therapies. Insufficient yield is a key contributor as demand continues to outpace supply. Innate antiviral defenses have emerged as an industry-wide issue impeding viral vector yield and quality.
BioSolve bioprocess modeling allows for the evaluation of benefits of enhancing technologies such as Viral Sensitizers (VSE™) by observing key cost drivers and identifying how they are influenced by even modest improvements in yield. Incorporating VSEs allows for robust scale-up of AAV8, and BioSolve unravels cost benefits for informed decision-making.